<p>MaxCyte, Inc. (NASDAQ:MXCT - 獲取免費報告) 的股價在週三交易中上漲了 0.7%。該公司股價最高達到 1.54 美元，最後交易價為 1.51 美元。在午盤交易中，約有 430,216 股成交，較平均每日成交量 627,622 股下降了 31%。該股票此前收盤價為 1.50 美元。</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p>MXCT 已成為多份研究報告的主題。Weiss Ratings 在 12 月 29 日的報告中重申了對 MaxCyte 股票的 &#34;賣出 (e+)&#34; 評級。Wall Street Zen 在 11 月 22 日的研究報告中將 MaxCyte 股票的評級從 &#34;賣出&#34; 上調至 &#34;持有&#34;。兩位股票研究分析師給予該股票買入評級，兩位給予持有評級，一位給予賣出評級。根據 MarketBeat 的數據，該股票的共識評級為 &#34;持有&#34;，共識目標價為 7.00 美元。</p>
<p><strong>查看我們關於 MaxCyte 的最新研究報告</strong></p>
<h2>MaxCyte 股價上漲 0.7%</h2>
<p>該公司 50 日移動平均線為 1.58 美元，200 日移動平均線為 1.69 美元。該股票的市值為 1.6107 億美元，市盈率為-3.43，貝塔值為 1.22。</p>
<p>MaxCyte (NASDAQ:MXCT - 獲取免費報告) 最近在 11 月 12 日發佈了季度財報。該公司報告每股收益（EPS）為（0.12）美元，低於市場共識預期的（0.11）美元，差額為（0.01）美元。MaxCyte 的淨利潤率為負 132.57%，股本回報率為負 23.50%。該公司在本季度的收入為 641 萬美元，而分析師預期為 837 萬美元。整體來看，研究分析師預測 MaxCyte, Inc. 本年度將發佈-0.42 的每股收益。</p>
<h2>對 MaxCyte 的對沖基金看法</h2>
<p>一些機構投資者最近增加或減少了對 MXCT 的持股。AQR Capital Management LLC 在第一季度將其在 MaxCyte 的持股增加了 227.3%。AQR Capital Management LLC 目前擁有 95,501 股該公司的股票，價值 261,000 美元，此前在上個季度增持了 66,323 股。Mudita Advisors LLP 在第一季度將其在 MaxCyte 的持股增加了 3.3%。Mudita Advisors LLP 目前擁有 3,328,441 股該公司的股票，價值 9,087,000 美元，此前在上個季度增持了 105,034 股。Strs Ohio 在第一季度購買了 MaxCyte 的新頭寸，價值約 328,000 美元。Farther Finance Advisors LLC 在第二季度將其在 MaxCyte 的持股增加了 7,935.4%。Farther Finance Advisors LLC 目前擁有 11,812 股該公司的股票，價值 26,000 美元，此前在上個季度增持了 11,665 股。最後，CWM LLC 在第二季度將其在 MaxCyte 的持股增加了 92.7%。CWM LLC 目前擁有 12,132 股該公司的股票，價值 26,000 美元，此前在上個季度增持了 5,836 股。機構投資者和對沖基金持有該公司 68.81% 的股票。</p>
<h2>MaxCyte 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>MaxCyte, Inc NASDAQ: MXCT 是一家臨牀階段的細胞治療平台公司，開發和商業化專有的流動電穿孔技術，以將大分子輸送到活細胞中。該公司的儀器和耗材旨在支持細胞治療的研究、臨牀前開發和臨牀規模生產，涵蓋多種模式，包括工程化 T 細胞、自然殺傷 (NK) 細胞和誘導多能幹細胞 (iPSC) 治療。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票，勝過 MaxCyte</li>
<li>你還認為白銀是個笑話嗎？看看接下來會發生什麼。</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>崩盤前一個月</li>
<li>埃隆將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>YDES 可能是 2026 年的生物科技突破</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 MaxCyte 嗎？</h2>
<p>在你考慮 MaxCyte 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MaxCyte 並不在名單上。</p>
<p>雖然 MaxCyte 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MXCT

<p>MaxCyte（納斯達克代碼：MXCT）股價上漲 0.7%，至 1.51 美元，交易量較平均水平下降 31%。分析師的評級不一：兩位買入，兩位持有，一位賣出，市場共識目標價為 7.00 美元。該公司報告的季度每股收益為（0.12 美元），未達到預期，收入為 641 萬美元。機構投資者持有該股票的 68.81%。MaxCyte 專注於細胞治療技術，用於將大分子輸送到活細胞中</p>

<p>MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report)'s share price was up 0.7% during trading on Wednesday . The company traded as high as $1.54 and last traded at $1.51. Approximately 430,216 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 627,622 shares. The stock had previously closed at $1.50.</p>
<div class="lb-trans"><p>MaxCyte, Inc. (NASDAQ:MXCT - 獲取免費報告) 的股價在週三交易中上漲了 0.7%。該公司股價最高達到 1.54 美元，最後交易價為 1.51 美元。在午盤交易中，約有 430,216 股成交，較平均每日成交量 627,622 股下降了 31%。該股票此前收盤價為 1.50 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p>MXCT has been the subject of a number of research reports. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of MaxCyte in a report on Monday, December 29th. Wall Street Zen upgraded shares of MaxCyte from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 22nd. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and a consensus price target of $7.00.</p>
<div class="lb-trans"><p>MXCT 已成為多份研究報告的主題。Weiss Ratings 在 12 月 29 日的報告中重申了對 MaxCyte 股票的 &#34;賣出 (e+)&#34; 評級。Wall Street Zen 在 11 月 22 日的研究報告中將 MaxCyte 股票的評級從 &#34;賣出&#34; 上調至 &#34;持有&#34;。兩位股票研究分析師給予該股票買入評級，兩位給予持有評級，一位給予賣出評級。根據 MarketBeat 的數據，該股票的共識評級為 &#34;持有&#34;，共識目標價為 7.00 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on MaxCyte</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 MaxCyte 的最新研究報告</strong></p>
</div><h2>MaxCyte Trading Up 0.7%</h2>
<div class="lb-trans"><h2>MaxCyte 股價上漲 0.7%</h2>
</div><p>The firm has a 50-day moving average of $1.58 and a 200 day moving average of $1.69. The stock has a market capitalization of $161.07 million, a price-to-earnings ratio of -3.43 and a beta of 1.22.</p>
<div class="lb-trans"><p>該公司 50 日移動平均線為 1.58 美元，200 日移動平均線為 1.69 美元。該股票的市值為 1.6107 億美元，市盈率為-3.43，貝塔值為 1.22。</p>
</div><p>MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. The firm had revenue of $6.41 million during the quarter, compared to analyst estimates of $8.37 million. As a group, research analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current year.</p>
<div class="lb-trans"><p>MaxCyte (NASDAQ:MXCT - 獲取免費報告) 最近在 11 月 12 日發佈了季度財報。該公司報告每股收益（EPS）為（0.12）美元，低於市場共識預期的（0.11）美元，差額為（0.01）美元。MaxCyte 的淨利潤率為負 132.57%，股本回報率為負 23.50%。該公司在本季度的收入為 641 萬美元，而分析師預期為 837 萬美元。整體來看，研究分析師預測 MaxCyte, Inc. 本年度將發佈-0.42 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On MaxCyte</h2>
<div class="lb-trans"><h2>對 MaxCyte 的對沖基金看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in MXCT. AQR Capital Management LLC grew its stake in shares of MaxCyte by 227.3% during the first quarter. AQR Capital Management LLC now owns 95,501 shares of the company's stock valued at $261,000 after acquiring an additional 66,323 shares in the last quarter. Mudita Advisors LLP boosted its holdings in MaxCyte by 3.3% in the first quarter. Mudita Advisors LLP now owns 3,328,441 shares of the company's stock valued at $9,087,000 after purchasing an additional 105,034 shares during the last quarter. Strs Ohio purchased a new position in MaxCyte in the first quarter valued at about $328,000. Farther Finance Advisors LLC grew its stake in MaxCyte by 7,935.4% during the 2nd quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company's stock valued at $26,000 after purchasing an additional 11,665 shares in the last quarter. Finally, CWM LLC increased its holdings in MaxCyte by 92.7% during the 2nd quarter. CWM LLC now owns 12,132 shares of the company's stock worth $26,000 after purchasing an additional 5,836 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者最近增加或減少了對 MXCT 的持股。AQR Capital Management LLC 在第一季度將其在 MaxCyte 的持股增加了 227.3%。AQR Capital Management LLC 目前擁有 95,501 股該公司的股票，價值 261,000 美元，此前在上個季度增持了 66,323 股。Mudita Advisors LLP 在第一季度將其在 MaxCyte 的持股增加了 3.3%。Mudita Advisors LLP 目前擁有 3,328,441 股該公司的股票，價值 9,087,000 美元，此前在上個季度增持了 105,034 股。Strs Ohio 在第一季度購買了 MaxCyte 的新頭寸，價值約 328,000 美元。Farther Finance Advisors LLC 在第二季度將其在 MaxCyte 的持股增加了 7,935.4%。Farther Finance Advisors LLC 目前擁有 11,812 股該公司的股票，價值 26,000 美元，此前在上個季度增持了 11,665 股。最後，CWM LLC 在第二季度將其在 MaxCyte 的持股增加了 92.7%。CWM LLC 目前擁有 12,132 股該公司的股票，價值 26,000 美元，此前在上個季度增持了 5,836 股。機構投資者和對沖基金持有該公司 68.81% 的股票。</p>
</div><h2>MaxCyte Company Profile</h2>
<div class="lb-trans"><h2>MaxCyte 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>MaxCyte, Inc NASDAQ: MXCT is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company's instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.</p>
<div class="lb-trans"><p>MaxCyte, Inc NASDAQ: MXCT 是一家臨牀階段的細胞治療平台公司，開發和商業化專有的流動電穿孔技術，以將大分子輸送到活細胞中。該公司的儀器和耗材旨在支持細胞治療的研究、臨牀前開發和臨牀規模生產，涵蓋多種模式，包括工程化 T 細胞、自然殺傷 (NK) 細胞和誘導多能幹細胞 (iPSC) 治療。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than MaxCyte</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>A month before the crash</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>YDES Could Be 2026's Biotech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 MaxCyte</li>
<li>你還認為白銀是個笑話嗎？看看接下來會發生什麼。</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>崩盤前一個月</li>
<li>埃隆將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>YDES 可能是 2026 年的生物科技突破</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MaxCyte Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 MaxCyte 嗎？</h2>
</div><p>Before you consider MaxCyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 MaxCyte 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MaxCyte 並不在名單上。</p>
</div><p>While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MaxCyte 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MaxCyte（NASDAQ:MXCT）股價上漲 0.7% - 現在是買入的好時機嗎？